Search Result

Results for "

metabolic+homeostasis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (1) Apoptosis (4) ATP-binding cassette (ABC) transporters (1) Bacterial (1) CaSR (1) DNA/RNA Synthesis (1) Endogenous Metabolite (4) ERK (2) Fructose-1,6-bisphosphate aldolase (1) FXR (1) Glucocorticoid Receptor (1) Histone Methyltransferase (1) HMG-CoA Reductase (HMGCR) (1) Interleukin Related (4) Isocitrate Dehydrogenase (IDH) (1) Mitochondrial Metabolism (1) Orphan Nuclear Receptor (1) PPAR (3) Ras (2) Sirtuin (1) STAT (2) TNF Receptor (1) Wnt (1) YAP (2) β-catenin (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (5) Metabolic Disease (8) Neurological Disease (1)

By Targets:

AMPK (1)

Apoptosis (4)

ATP-binding cassette (ABC) transporters (1)

Bacterial (1)

CaSR (1)

DNA/RNA Synthesis (1)

Endogenous Metabolite (4)

ERK (2)

Fructose-1,6-bisphosphate aldolase (1)

FXR (1)

Glucocorticoid Receptor (1)

Histone Methyltransferase (1)

HMG-CoA Reductase (HMGCR) (1)

Interleukin Related (4)

Isocitrate Dehydrogenase (IDH) (1)

Mitochondrial Metabolism (1)

Orphan Nuclear Receptor (1)

PPAR (3)

Ras (2)

Sirtuin (1)

STAT (2)

TNF Receptor (1)

Wnt (1)

YAP (2)

β-catenin (1)

By Research Areas:

Cancer (4)

Cardiovascular Disease (1)

Infection (1)

Inflammation/Immunology (5)

Metabolic Disease (8)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-126370A

Geranylgeranyl pyrophosphate triammonium	Endogenous Metabolite YAP Apoptosis Interleukin Related STAT ERK Ras	Cancer
Geranylgeranyl pyrophosphate triammonium is a type of isoprenoid metabolic intermediate, mainly synthesized through the mevalonate pathway. Geranylgeranyl pyrophosphate triammonium is a key precursor in various biological synthesis processes, especially as a necessary substrate for post-translational modification of proteins - geranylgeranyl phosphorylation. Geranylgeranyl pyrophosphate triammonium regulates various cellular processes and disease progression through protein geranylgeranyl phosphorylation, such as activating the YAP signaling pathway, promoting cell proliferation and inhibiting apoptosis; promoting IL-2 production and STAT5 phosphorylation; and influencing metabolic homeostasis and cancer, etc .

HY-N9933

Tauro-β-muricholic acid 4 Publications Verification TβMCA	FXR Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Tauro-β-muricholic acid (TβMCA) is an orally active trihydroxylated bile acid and a competitive, reversible FXR antagonist (IC₅₀=40 μM). Tauro-β-muricholic acid inhibits bile acid-induced hepatocyte apoptosis by maintaining mitochondrial membrane potential, while simultaneously inhibiting intestinal FXR signaling, affecting bile acid synthesis, hepatic lipid metabolism, and insulin sensitivity. Accumulation of tauro-β-muricholic acid disrupts metabolic homeostasis, promoting cancer stem cell proliferation and tumor progression. The mechanisms of tauro-β-muricholic acid involve two aspects: first, inhibiting the translocation of the pro-apoptotic protein Bax to mitochondria and maintaining mitochondrial membrane potential (MMP); and second, blocking the FXR signaling pathway to regulate bile acid metabolism, reduce serum ceramide production, and downregulate the hepatic SREBP1C/CIDEA pathway. Tauro-β-muricholic acid possesses anti-hepatocyte apoptosis, bile acid homeostasis regulation, and liver fat accumulation reduction properties, and also functions as a biomarker, making it useful in the study of diseases such as bile acid metabolism disorders, non-alcoholic fatty liver disease, colorectal cancer, and liver fibrosis .

HY-113114

Tetrahydrocortisone	Endogenous Metabolite Glucocorticoid Receptor	Metabolic Disease Inflammation/Immunology
Tetrahydrocortisone is a corticosteroid catalyzed from endogenous glucocorticoids by AKR1D1 (5_β-reductase). Its formation is mediated by AKR1D1 and regulated by the glucocorticoid receptor (GR). As one of the final products of glucocorticoid inactivation metabolism, Tetrahydrocortisone participates in the maintenance of glucocorticoid metabolic homeostasis in vivo. Tetrahydrocortisone can be used for mechanistic studies of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes, and also serves as a biomarker for in vivo AKR1D1 activity and glucocorticoid metabolic status .

HY-148189

Aldometanib Maximum Cited Publications 9 Publications Verification LXY-05-029	Fructose-1,6-bisphosphate aldolase AMPK	Metabolic Disease
Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib can activate lysosomal adenosine monophosphate-activated protein kinase (AMPK) and decreases blood glucose. Aldometanib can be used for the research of metabolic homeostasis .

HY-125130

Hesperetin 7-O-glucoside 1 Publications Verification Hes-7-G	HMG-CoA Reductase (HMGCR) Bacterial Interleukin Related	Infection Metabolic Disease Inflammation/Immunology
Hesperetin 7-O-glucoside is a typical flavonoid monoglucoside, which is an anti-inflammatory agent and an antihypertensive with orally active. Hesperetin 7-O-glucoside is a commonly used food adjuvant. Hesperetin 7-O-glucoside inhibits human intestinal maltase and human HMG-CoA reductase with K_i of 1.8 mM and 9.8 μM, respectively. Hesperetin 7-O-glucoside has antibacterial activity and can regulate intestinal flora and metabolic homeostasis in mice .

HY-128661

IDH1 Inhibitor 2 4 Publications Verification	Isocitrate Dehydrogenase (IDH)	Metabolic Disease
IDH1 Inhibitor 2 (compound 13) is a potent wild-type IDH1 inhibitor that exerts its activity through covalent modification of His315 with an IC₅₀ value of 110 nM. IDH1 Inhibitor 2 can dose-dependently reduce the intracellular reduced glutamine metabolic flux, thereby affecting cellular metabolic homeostasis. IDH1 Inhibitor 2 can be used to study the role of IDH1 in cellular metabolic regulation and cancer development .

HY-126370

Geranylgeranyl pyrophosphate	Endogenous Metabolite YAP Apoptosis Interleukin Related STAT ERK Ras	Cancer
Geranylgeranyl pyrophosphate is a type of isoprenoid metabolic intermediate, mainly synthesized through the mevalonate pathway. Geranylgeranyl pyrophosphate is a key precursor in various biological synthesis processes, especially as a necessary substrate for post-translational modification of proteins - geranylgeranyl phosphorylation. Geranylgeranyl pyrophosphate regulates various cellular processes and disease progression through protein geranylgeranyl phosphorylation, such as activating the YAP signaling pathway, promoting cell proliferation and inhibiting apoptosis; promoting IL-2 production and STAT5 phosphorylation; and influencing metabolic homeostasis and cancer, etc .

HY-12557

γ-Glutamylvaline γ-Glu-Val	Endogenous Metabolite CaSR Wnt TNF Receptor Interleukin Related PPAR β-catenin	Inflammation/Immunology
γ‑Glutamylvaline (γ-Glu-Val) is a calcium‑sensing receptor (CaSR) agonist. γ‑Glutamylvaline activates CaSR and facilitates its binding to β‑arrestin 2 to modulate inflammatory and metabolic homeostasis signaling. γ‑Glutamylvaline inhibits TNF‑α‑induced IL‑6/MCP‑1 and enhances adiponectin/PPARγ in adipocytes. γ‑Glutamylvaline upregulates Wnt5a, restores β‑catenin phosphorylation, and reduces serine‑phosphorylated IRS‑1 in adipocytes. γ-Glutamylvaline can be used for the research of low-grade chronic inflammation .

HY-131445B

RR-RJW100 1 Publications Verification	Orphan Nuclear Receptor	Metabolic Disease
RR-RJW100, the enantiomer of RJW100, is an nuclear receptor liver receptor homolog 1 (LRH-1) and steroidogenic factor 1 (SF-1) agonist. RJW100 can be synthesized as two enantiomers, RR-RJW100 and SS-RJW100, with RR-RJW100 shown to be the more potent LRH-1 agonist. RR-RJW100 is involved in the regulation of metabolic homeostasis and is used in studies of diabetes, liver disease and inflammatory bowel disease .

HY-143862

Pparδ agonist 7	PPAR	Metabolic Disease
Pparδ agonist 7 is a potent agonist of Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ agonist 7 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2019105234A1, compound TM4) .

HY-118109

SIRT3-IN-2	Sirtuin
SIRT3-IN-2 (Inhibitor scaffolds in Scheme 1) is a SIRT3 inhibitor, reducing SIRT3 activity by 39% at a concentration of 200 µM. SIRT3-IN-2 is promising for research into metabolic homeostasis and tumor suppression .

HY-143863

PPARδ agonist 8	PPAR	Metabolic Disease
Pparδ agonist 8 is a potent agonist of Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ agonist 8 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2021169769A1, compound TM2) .

HY-186045

SKLB06489	Histone Methyltransferase Apoptosis DNA/RNA Synthesis ATP-binding cassette (ABC) transporters	Cancer
SKLB06489 is a selective and orally active inhibitor of type I PRMT enzymes, with IC₅₀ values of 64.55 nM (PRMT1), 4.21 nM (PRMT6), and 51.27 nM (PRMT8). SKLB06489 inhibits cell proliferation, colony formation, DNA replication, and DNA damage repair in cancer cells. SKLB06489 induces G0/G1-phase cell cycle arrest and apoptosis in cancer cells. SKLB06489 enhances intracellular cholesterol efflux via ABCA1 and ABCG1 upregulation, disrupts cholesterol metabolic homeostasis, and suppresses tumor growth in subcutaneous xenograft models. SKLB06489 can be used for the research of triple-negative breast cancer (TNBC) .

HY-131453

Mitochondrial respiration-IN-1	Mitochondrial Metabolism	Cardiovascular Disease Inflammation/Immunology
Mitochondrial respiration-IN-1 is a mitochondrial respiratory inhibitor. Mitochondrial respiration-IN-1 reduces platelet aggregation, adhesion, and platelet-induced coagulation responses. Mitochondrial respiration-IN-1 induces adaptive glycolysis, decreases mitochondrial membrane potential, selectively reduces ATP production derived from oxidative phosphorylation, and exerts bidirectional regulatory effects on cell proliferation. Mitochondrial respiration-IN-1 activates UPRmt and upregulates the expression of SDHA-1 and MT-CO1. Mitochondrial respiration-IN-1 restores metabolic homeostasis in type 2 diabetic mice. Mitochondrial respiration-IN-1 can be used to investigate diseases mediated by inappropriate platelet activation/aggregation and type 2 diabetes .

Cat. No.	Product Name	Target	Research Area